Demographics

View past meeting statistics and demographic information for the Annual Meeting.

2017 Registration Numbers

  • Total—39,400
  • Professionals—32,100
  • Exhibitors—5,400
  • Spouse, Guest, Media—1,900
  • Domestic Attendees—53%
  • International Attendees—47%

Top 10 Countries in Attendance in 2017

  • United States—17,168
  • Japan—1,444
  • Germany—1,249
  • France—1,223
  • United Kingdom—1,048
  • China—993
  • Canada—848
  • Brazil—757
  • Switzerland—653
  • Italy—537

Primary Professional Role in 2017

Primary Professional Role Percentage of Attendees who Responded
Physician 40%
Other 34%
Researcher 9%
Marketing Representative 4%
Business Administrator 3%
Pharmacist 3%
Sales Representative 2%

Biostatistician / Epidemiologist

1%
Student 1%
Office Manager 1%
Nurse 1%

Financial Service Representative

1%

Attendees were allowed to choose only one answer. Responded— 31,200 (97%). No Response—900 (3%). Total—32,100             

Board Certification or International Equivalent in 2017

Board Certification or International Equivalent Percentage of Attendees who Responded
Medical Oncology 35%
Not Applicable 29%
Internal Medicine 22%
Hematology 14%
Oncology Pharmacy 5%
Other 5%
Laboratory Research 4%
Pharmacology (Clinical) 4%
Surgery (including Surgical Oncology and Surgical Specialties) 3%
Biostatistics / Epidemiology 3%
Radiation Oncology 3%
Gynecologic Oncology 3%
Pediatics (including Pediatric Oncology and Pediatric Specialties) 2%
Allied Health (e.g. Psychology, Physical Therapy, Social Work, etc.) 2%
Clinical Informatics 2%
Urology / Urologic Oncology 2%
Gastroenterology 2%
Pathology 2%
Oncology Nursing 2%
Health Care Administration 1%
Neurology 1%
Hospice and Palliative Medicine 1%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded—20,900 (65%). No Response—11,200 (35%). Totals—32,100 

Primary Interest in 2017

Primary Interest Percentage of Attendees who Responded
Clinical Trials 38%
Breast Cancer 35%
Lung Cancer 32%
Gastrointestinal (Colorectal Cancer) 21%
Developmental Therapeutics and Translational Research 20%
Tumor Biology 18%
Hematologic Malignancies - Lymphoma and CLL 15%
Gastrointestinal (Noncolorectal Cancer) 13%
Melanoma / Skin Cancers 12%
Hematologic Malignancies - Leukemia, MDS, and Allotransplant 12%
Cancer Prevention, Genetics, and Epidemiology 12%
Genitourinary (Prostate) Cancer 11%
Head and Neck Cancer 10%
Gynecologic Oncology 9%
Genitourinary (Nonprostate) Cancer 8%
Professional Development 7%
Hematologic Malignancies - Plasma Cell Dyscrasia 6%
Health Services Research, Clinical Informatics and Quality of Care 6%
Patient and Survivor Care 6%
Sarcoma  5%
Central Nervous System Tumors 5%
Pediatric Oncology 4%
Care Delivery and Practice Management 4%
Disparities / Access to Care 4%
Other 3%
Ethics 2%
Value 2%
Geriatric Oncology 2%

*Some attendees chose more than one response therefore the total number of responses is greater than the total number of attendees who responded. Responded— 20,350 (63%). No Response—11,750 (37%). Totals—32,100     

2016 Abstract Statistics 

Abstracts Submitted: 5,817

  • 5,225 Regular submissions
  • 60 Late-breaking data submissions
  • 532 Trials in Progress submissions

Accepted for Presentation: 2,463 (42%), ePublication Only: 2,777 (48%), Rejected or Withdrawn before Review: 577 (10%).

Abstract Submissions by Track in 2016

Track Number of Submissions
Breast Cancer—HER2/ER 252
Breast Cancer—Triple Negative/Cytotoxics/Local Therapy 197
Cancer Prevention, Hereditary Genetics, and Epidemiology 241
Central Nervous System Tumors 152
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics 307
Developmental Therapeutics—Immunotherapy 246
Gastrointestinal (Colorectal) Cancer 356
Gastrointestinal (Noncolorectal) Cancer 468
Genitourinary (Nonprostate) Cancer 271
Genitourinary (Prostate) Cancer 248
Gynecologic Cancer 266
Head and Neck Cancer 185
Health Services Research and Quality of Care 459
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant 154
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia 182
Hematologic Malignancies—Plasma Cell Dyscrasia 79
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 196
Lung Cancer—Non-Small Cell Metastatic 309
Melanoma/Skin Cancers 197
Patient and Survivor Care 380
Pediatric Oncology 106
Sarcoma 136
Tumor Biology 430

*Submissions were received from 82 countries in 2016. There were 2,967 domestic submissions (51%) and 2,850 international (49%).

Top International Countries By Abstract Submission in 2016

China: 279
Japan: 270
France: 245
Canada: 242
Germany: 199
U.K.: 195
Italy: 186
Spain: 155

Clinical Trials and Funding

1,995 Abstracts Reported “Yes” to Clinical Trial

  • 1,139 Funded by a Pharmaceutical/Biotech Company
  • 542 Funded by Academic Institution or International Federal Agencies
  • 168 Funded by a Foundation
  • 146 Funded by National Institutes of Health (NIH)